Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG06466 PET Study in Healthy Men
NCT05219838Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABX-1431 in post-traumatic stress disorder (PTSD) and focal epilepsy (2 arms), sponsored by Lundbeck. Primary endpoints: Plasma Concentration of Lu AG06466 and Lu AG06988 at Day 6, Cerebrospinal Fluid (CSF) Concentration of Lu AG06466 and Lu AG06988 at Day 6 and 2 more. Started Jan 2022; status: completed.
02
Drugs
ABX-1431
03
Conditions
post-traumatic stress disorder (PTSD)focal epilepsy
Beyond the preview
Go deeper on NCT05219838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219838.